guardant health investment thesis

Yet, amid pandemic-related concerns over its revenue growth, the first-ever regulatory win hasn’t sparked the share price rally that usually follows such announcements. Gets Its Catalyst And Trades Up: Twitter Inc. (TWTR), Guardant Health Inc. (GH) By. Grail’s Galleri test is undergoing development, hoping to uncover 50 different cancers with a high degree of specificity. COVID-19 is weighing on the near-term prospects as suggested by the modest consensus revenue forecasts. Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains. The ongoing clinical trials will only accelerate the rising cash burn. Both tests feed the development of the company’s LUNAR program. I think that this stock has the kind of X factor that every investor should like. Investment Thesis. One of the most important of these was the decision by Palmetto GBA to make Guardant360 the first (and, so far, only) liquid biopsy to receive broad coverage for use in most types of advanced solid tumors. The stock closed at an all-time high on Feb. 21, 2020. An even greater opportunity for Guardant Health, though, lies with its LUNAR liquid biopsies, which are currently available for research use only. According to Illumina, early detection could make up ~61% of the global market for cancer genetic sequencing, which is growing at 27% of CAGR (compound annual growth rate) to reach $75 billion by 2035. The lukewarm growth forecasts seen in consensus revenue and the … A subsequent respite in the virus spread will likely accelerate the recovery in test volumes as patients eventually return to doctors’ offices to seek cancer care, something they cannot postpone indefinitely. The total Institutional investors and hedge funds own 84.80% of … With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection tests. 1. LUNAR-2 could enable the detection of cancer at early stages. Guardant Health, Inc. (Nasdaq: GH) today announced the pricing of its offering of $1,000,000,000 aggregate principal amount of 0% convertible senior notes due … Twitter. LUNAR-2 has a much larger addressable market of more than $30 billion. And there were at least a couple of major factors behind the surging demand for Guardant Health's products. However, it doesn’t have repeat customers like Guardant Health where patients need to get retested every so often. I have no business relationship with any company whose stock is mentioned in this article. The NTM EV/Sales is also trading at a discount compared to historicals. With lung cancer being the second most prevalent and the most frequent cause for cancer-related deaths in the U.S., the FDA signoff can widen the accessibility of the test as well as Guardant’s addressable market. With the FDA approval for Guardant360, Guardant Health, Inc. has achieved a milestone for its broad array of cancer detection tests. I don't think so. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. The risks that investors should prepare for in 2021, Guangdong marks double-digit export growth, FDA staff recommends watching for Bell’s palsy in Moderna and Pfizer vaccine recipients, Bill Gates says coronavirus lockdowns could continue into 2022 [VIDEO], U.S. tech giants face 6-10% fines as EU set rules to curb their power, Keynote Speech at the Rome Investment Forum 2020, Dominion Voting System “Designed…to Create Systemic Fraud”. Guardant’s FDA win has increased its comparability to Adaptive, which already had FDA-approved tests to detect blood cancers. Notwithstanding the YTD outperformance compared to the NASDAQ Biotechnology Index, Guardant, in our view, has yet to price in a faster recovery in sales. The test volumes from biopharma customers, generating ~37.1% of the top-line, will expand at a similar rate to the past quarter. NVDA. Roche (SIX:ROG; OTCQB:RHHBY), Basel, Switzerland. WhatsApp. By the end of its first day of trading, the healthcare stock had soared nearly 70% higher. Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. This accolade is a … With COVID-19 being responsible for about 30% of the mortality rate in cancer patients, the virus fears have discouraged the patients from visiting cancer clinics. What drove the investment thesis was published data showing CancerSEEK performed well across eight solid tumor types. Facebook. Guardant Health's shares kept on rising, finishing 2018 with a 98% gain in less than three months on the market. But margin expansion hasn’t offset the impact from shrinking revenue growth, and for the second quarter in a row, the operating loss has widened by multiple times from a year ago. This study pitted Guardant Health's liquid biopsy against standard-of-care tissue testing in detecting key biomarkers in patients with advanced non-small-cell lung cancer (NSCLC). Guardant Health. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. The lukewarm growth forecasts seen in consensus revenue and the discount in trading multiple compared to the historical average underscore the concerns. Finance. Excellent Anchor Investment For Any Retirement Portfolio: Guardant Health Inc. (GH)... Edward Bosworth-November 5, 2020. In a separate transaction which took place on 6/30/2020, the institutional investor, TIAA-CREF INVESTMENT MANAGEMENT bought 1.1 million shares of the company’s stock. The potential U.S. market for LUNAR-1 is around $15 billion. Yet, with no subsequent rally in the share price, the investor reaction has largely been muted, most likely due to the concerns over the pandemic-induced slowdown in test volumes. Let's conquer your financial goals together...faster. Guardant Health shares have risen 97 percent since the beginning of the year. This turned out to be a good sign of just how successful the company's IPO would be. Janssen Biotech has already teamed up with Guardant to develop and commercialize Guardant360 as a companion diagnostic for its experimental NSCLC therapy, amivantamab. Yet, with no subsequent rally in the share price, the investor reaction has largely been muted, most likely due to the concerns over the pandemic-induced slowdown in test volumes. The stock market plunged as the novel coronavirus and the disease that it causes, COVID-19, spread across the world. Market data powered by FactSet and Web Financial Group. flipped into Stock Ideas. Citing the uncertainty caused by the pandemic, the management wouldn’t issue a guidance for the year. Investment Thesis With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection tests. The consensus estimate for 2020 reflects the gloomy outlook. With our more upbeat sales forecasts, the 2019 average in NTM EV/Sales indicates a sharp premium. Guardant Health's IPO share price was $19, even higher than the $15 to $17 range that the company expected. The lukewarm growth forecasts seen in consensus revenue and the … Anna has 6 jobs listed on their profile. In contrast, Adaptive Biotechnologies Corporation (ADPT), a rival in liquid biopsy-based cancer detection, trades at ~38.8x in terms of NTM EV/Sales with only a ~9.6% discount to its 2019 average. The burst in test volume growth seen in 2019 has come to a grinding halt. The one investment that's never let long-term investors down. Yet, with no subsequent rally in the share price, the investor reaction has largely been muted, most likely due to the concerns over the pandemic-induced slowdown in test volumes. If Guardant Health can capture a significant share of these markets, its long-term returns could make the 360% gain since its IPO look like chump change. Exact Sciences Corp. said it will acquire Thrive Earlier Detection Corp. to gain technology for cancer screening in a deal worth as much as $2.15 billion. Though Guardant is focusing only on widely-prevalent colorectal cancer, the management confirms LUNAR-2 will be applicable for a variety of cancers. Last year, ... Guardant Health Inc. (NASDAQ:GH), Redwood City, Calif. Johns Hopkins University, Baltimore, Md. Via SeekingAlpha.com, Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains (NASDAQ:GH), Rouhani Says Iran Would Rejoin Nuclear Deal "Within An Hour" Of US Signing On, Federal Reserve’s final meeting of 2020: four things to watch, Electronic Arts lines up counter-offer for Codemasters. I am not receiving compensation for it (other than from Seeking Alpha). During 2019, Guardant Health's share price more than doubled. View Anna Chen Ph.D.’s profile on LinkedIn, the world's largest professional community. If you enjoyed this article and wish to receive updates on my latest research, click “Follow” next to my name at the top. 0. As investors, we're taught one simple truth: Nothing is guaranteed. The recent FDA signoff for Guardant360 hasn’t fueled the expected share price rally in Guardant. Great Protection In An Uncertain Environment: Guardant Health Inc. (GH) and... Edward Bosworth-November 7, 2020. That's still a fantastic performance even with the recent coronavirus-fueled decline. A look at the technology behind Guardant's diagnostics system, and some speculation as to which companies might be a potential suitor in a buyout I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. https://seekingalpha.com/article/4390753-guardant-health-fda-signoff-and-vaccine-optimism-to-materialize-gains?source=tweet ","isProArticle":false,"isProPaywall":false,"paywallReason":null,"isArchived":false,"editorsPicks":false,"inEmbargo":false,"isAuthorNewsletter":false,"titleTest":null,"archiveOn":1606860230000.0,"isProNoEmbargo":false,"url":"https://seekingalpha.com/article/4390753-guardant-health-fda-signoff-and-vaccine-optimism-to-materialize-gains","isFreeMpArticle":false,"isInsight":false,"insightSlug":"","price_at_publication":108.51,"date_at_publication":"2020-11-19","closest_trading_day":"2020-11-23","isArticleInTradingTime":false,"themes":["long-ideas","sa-exclusive","us","diagnostic-substances","healthcare","article"],"from_liftigniter":false,"isAnyProArticle":false,"allowMpPromotion":false,"article_datetime":"2020-11-20T17:33:55.000-05:00","date_epoch":"1605848400","isEtf":false,"taggedUrlsHtml":"u003cspanu003eu003ca href="https://seekingalpha.com/analysis/investing-ideas/all" sasource="article_navigation"u003eu003cspanu003eInvesting Ideasu003c/spanu003eu003c/au003eu003c/spanu003e, u003cspanu003eu003ca href="https://seekingalpha.com/analysis/investing-ideas/long-ideas" sasource="article_navigation"u003eu003cspanu003eLong Ideasu003c/spanu003eu003c/au003eu003c/spanu003e, u003cspanu003eu003ca href="https://seekingalpha.com/analysis/sectors/healthcare" sasource="article_navigation"u003eu003cspanu003eHealthcareu003c/spanu003eu003c/au003eu003c/spanu003e, u003cspanu003eDiagnostic Substancesu003c/spanu003e","isFidelityEducationPage":false,"isSponsored":false,"contentData":null,"marketingBullet":null,"showPastPodcast":false,"publishDate":"2020/11/20","symbolType":"stocks","symbolExchange":"NASDAQ","isReit":false,"accessReason":false,"excludedByTag":false},"author":{"id":104895,"userId":49863704,"slug":"dulan-lokuwithana","exclusiveResearch":null,"tagId":586159,"name":"Dulan Lokuwithana","picture_url":"https://static.seekingalpha.com/images/users_profile/049/863/704/big_pic.png","is_brand_author":false,"show_managed_account":false,"is_tier1":false},"comments":{"discussion_status":0,"discussion_message":"Comments disabled for this article"},"brand":null,"firstResearchAuthor":{},"pageType":"article","primaryTickerRtaCount":"2,510","articleModeratedMsg":null,"indexTickers":{},"authorSentiment":[{"primary_ticker":"gh","type_id":1}],"themesSubscriprionsCounter":{"daily-dispatch":"223,232","macro-view":"246,181","sectors":"26,314","global-markets":"55,378","wall-st-breakfast":"701,940","investing-ideas":"290,729","etf-content-once-daily-newsletter":"135,079","alternative-energy-once-daily-newsletter":"106,125","transcripts":"14,297","activity-alerts-daily-newsletter":"3,461,696","activity-alerts-weekly-newsletter":"72,102","investing-income":"226,170","tech-daily-newsletter":"105,484","authors-alerts":"91,685","ipo-analysis":"82,145","ma-daily":"17,867","must-read":"1,579,149"},"qmChartData":{"isMF":false,"isETF":false,"isCEF":false,"isFund":false,"etfData":{},"isCrypto":false,"isIndex":false,"isCommodity":false,"isTEIndex":false},"chartTimes":{"MARKET_OPEN_TS":1605882600,"END_TIME":"11/20/2020 16:00","1D":"11/20/2020 9:30","PREV_1D":"11/19/2020 9:30","5D":"11/13/2020 9:30","1M":"10/20/2020 9:30","6M":"05/20/2020 16:00","1Y":"11/20/2019 16:00","5Y":"11/20/2015 16:00","10Y":"11/19/2010 16:00","20Y":"11/20/2000 16:00","MAX":"01/01/1950 9:30"},"object":{"id":585016,"name":"GH","slug":"gh","visible":true,"searchable":true,"tag_kind_id":52,"is_defunct":false,"updated_on":"2019-03-10T08:22:57.000-04:00","created_at":null,"content":"Guardant Health, Inc."}},"Ads":{"slots":[{"container":"article-left-slot-2","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":160},"size":[[160,600],"fluid"],"str":"160x600,fluid"}},{"container":"article-left-slot-3","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":162},"size":[[160,600],"fluid"],"str":"160x600,fluid"},"delay":true,"whenOutOfView":"article-left-slot-2","sticky":true},{"container":"article-right-slot-1","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":1},"size":[[300,250],[300,600],[300,1050],"fluid"],"str":"300x1050,300x250,300x600,fluid"},"cls":"mb25","flex":true},{"container":"article-right-slot-2","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":100},"size":[[300,100],[300,26],"fluid"],"str":"300x100,300x26,fluid"},"cls":"mb25"},{"container":"article-right-slot-3","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":2},"size":[[300,252],"fluid"],"str":"300x252,fluid"},"cls":"mb25","native":true},{"container":"article-middle-slot-1","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{},"size":[[640,40]],"str":"640x40"}},{"container":"ad_728x90","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":728},"size":[[728,90],[970,250],"fluid"],"str":"728x90,970x250,fluid"},"delay":true,"delta":500},{"container":"pushdown_top_ad","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":970},"size":[[970,250],[728,90],"fluid"],"str":"728x90,970x250,fluid"}},{"container":"instream_recommendation_ad","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":50},"size":["fluid"],"str":"fluid"},"delay":true,"delta":500}],"testScroll":true,"disabled":false,"kvs":{"d":["analysis","investing-ideas","sectors"],"t":["stock-ideas","long-ideas","sa-exclusive","us","diagnostic-substances","healthcare","article"],"aid":"4390753","mp_free_article":"false","prstock":"true","sen":"1","a":"dulan-lokuwithana","cnt":["15","27","36","oil","fed","taxes","tech","bny","ssga1","fnk1","fnk2","port","fnk3","fnk4","loan","NYL1","fnk6","fnk7","wf13","wf15","wf17","wf18","wf19","threadneedle_listt","fnk14","trowe_list","cvd19","fnk14t"],"pr":"gh","s":"gh","ab_news_page":"cp_news_page","ab_article_logged_out":"control"}},"Paths":{"int":{"adsAPI":{"src":"https://static.seekingalpha.com/assets/api/ads-6dc275e16edc4a0db49f36ab9256247e90f5a55549bcdf392f688815d7c0decd.js","id":"sa-ads-api"}},"ext":[{"src":"https://js-sec.indexww.com/ht/p/183642-250088771154532.js","id":"ie"},{"src":"https://www.googletagservices.com/tag/js/gpt.js","id":"gpt"},{"src":"https://sb.scorecardresearch.com/beacon.js","id":"sb"},{"src":"https://www.googletagmanager.com/gtm.js?id=GTM-PFXR76F","id":"gtm"},{"src":"https://connect.facebook.net/en_US/sdk.js","id":"facebook-jssdk"}]},"lastRequested":"2020-11-20 20:34:36 -0500","SlugsPrices":{"disabled":false},"saSource":null,"name":"article","useSQuoteSource":"iex"},"headerConfig":{"noNotificationsMenu":null,"nonFixed":null,"tabless":null,"activeTab":null},"modules":{},"requires":[],"trackq":[],"exceptions":[],"gptInit":false}; These results also helped pave the way for Guardant Health to pick up key reimbursement deals and coverage decisions from payers. Stock Advisor launched in February of 2002. After back-to-back declines sequentially, the total test volumes in Q3 2020 have jumped ~21.3% from the previous quarter. Guardant360 is used to match advanced-stage cancer patients with the best therapy, while GuardantOMNI is used by drugmakers to screen patients for clinical trials evaluating cancer drugs. Investment Thesis. Meanwhile, thanks to advances in genomics, precision-driven cancer treatments are gaining momentum. Edward Bosworth - September 3, 2020. However, as the coronavirus cases showed signs of easing in August following the surge in early summer, a slight recovery has begun in Q3 2020. Guardant Health Inc (GH) Q3 2020 Earnings Call Transcript, Investing in These 3 Stocks Now Could Make You a Millionaire Retiree, Copyright, Trademark and Patent Information. Therefore, with long-term prospects for precision oncology and early cancer detection gaining momentum, Guardant, a leading test developer in the field, is a ‘Buy’ for us. Returns as of 12/15/2020. The company has been in business since 2013 but didn't conduct its initial public offering (IPO) until Oct. 4, 2018. Guardant Health held its initial public offering (IPO) in October 2018. I wrote this article myself, and it expresses my own opinions. As the company’s long-term prospects in early cancer detection and the precision-oncology outweigh the near-term risks from COVID-19, Guardant is a compelling ‘Buy’ for us. The COVID-19 case counts are rising in record numbers in the U.S., and according to health experts, the worst has yet to come as winter approaches. Companies . Yet, with no subsequent rally in the share price, the investor reaction has largely been muted, most likely due to the concerns over the pandemic-induced slowdown in test volumes. Then the pandemic spread across the U.S., where Guardant sources ~90.6% of its revenue. The deceleration compared to ~22.5% YoY growth in Q3 2020 mirrors the management comments. Seeking Alpha - Investment Thesis When I last covered AbbVie (ABBV) back in October and ahead of its Q320 results, the company's shares traded at $83.5 and were in a … Landscape version of the Flipboard logo. Investment Thesis With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection tests. From ~47.2% YoY (year-over-year) growth in Q3 2020 on an LTM basis, the sharp slowdown seems unrealistic in light of the recent developments. Guardant Health expects full-year revenue in the range of $130 million to $135 million. Guardant recorded the highest ever quarterly gross margins in Q3 2020. Open in app; Sign up. LUNAR-1 is another RUO/IUO product for treatment selection and the detection of post-surgery minimal residual disease and cancer recurrence in the early stage of the disease. Investment Thesis. In September, Illumina, Inc. (ILMN) paid $7.1 billion in cash and stock to acquire GRAIL, Inc. (GRAL), a developer of liquid biopsy-based tests for early detection. Selective Estrogen Receptor Degrader in Phase III Trial For Use in Resistant ER-Positive Breast CancerREDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Guardant Health… Tag: Guardant Health Inc. Companies. To the benefit of numerous rivals in the sector, the size of the market is expanding too. Backed by better payer coverage for its late-stage cancer detection test, Guardant Health, Inc. has seen its top-line rising more than a two-fold from the previous year. Indicating ~32.9% YoY growth, ~$284.9 million of consensus revenue forecast for 2020 implies ~21.6% YoY growth for Q4 2020. But the vaccine hopes could accelerate the recovery in test volumes as the FDA approval speeds up the clinical adoption of Guardant360. Guardant Health thinks that its Guardant360 liquid biopsy has a $6 billion addressable annual market in the U.S. alone. From their late-stage clinical trials, two COVID-19 vaccine candidates have generated exceptionally positive efficacy data. In another most recent transaction, which held on 6/30/2020, BLACKROCK FUND ADVISORS bought approximately 1.4 million shares of Guardant Health Inc. * Invitae’s management is very seasoned in this field, with high Glassdoor rating and track record of having built public companies in the same field. The initial investment has delivered a return of over 360% in less than 20 months. Yet, the vaccine hopes could reverse the pandemic-related slowdown. The key to this success was the skyrocketing demand for Guardant Health's two liquid biopsy products, Guardant360 and GuardantOMNI. Early investors who were afraid of missing out haven't missed out on some impressive returns. Cumulative Growth of a $10,000 Investment in Stock Advisor, If You Invested $10,000 in Guardant Health's IPO, This Is How Much Money You'd Have Now @themotleyfool #stocks $GH, reported impressive results in February 2019, Why Guardant Health Tumbled by Over 10% on Monday. Could Solar Power Save The Lone Star State? When they arrive on the scene, investors flock to them. Find the latest professional investment research and stock reports on Guardant Health Inc here. With EV at 28.5x of 12-month forward sales, the company trades at a ~24.8% discount to its 2019 average of ~37.9x. Stocks. It's usually because there's a perception that the companies are on to something big. I have no business relationship with any company whose stock is mentioned in this article. Guardant Health delivered these tremendous gains the old-fashioned way. User Sign In. By comparison, the company's … Sign up today for full access. Guardant Health thinks that its Guardant360 liquid biopsy has a $6 billion addressable annual market in the U.S. alone. The most promising test, under development seeking FDA approval and CMS coverage, the LUNAR-2 assay targets early cancer detection in asymptomatic and high-risk individuals. Assuming a faster pickup in test volumes than suggested by the consensus, we project ~42.1 – 47.2% YoY growth in LTM revenue for the company, leading to ~$385.5 – ~$399.3 million in revenue. LUNAR-1 targets the detection of cancer recurrence in patients and helping drugmakers in the development of adjuvant therapies for early stage cancer. Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return. I am not receiving compensation for it (other than from Seeking Alpha). Nearly $36,250. By comparison, the company's total revenue last year was $214.4 million. Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. On an LTM (last twelve-month) basis, the company’s top-line had more than doubled compared to the year-ago period for four consecutive quarters through Q1 2020 (first quarter of 2020). Elon Musk says first Mars colony settlers will live in ‘glass domes’ before terraforming planet, China could join massive Asia-Pacific trade deal abandoned by US, IEA: Jet Fuel Will Continue Be A Drag On Oil Demand Recovery, Joe Biden picks primary rival Pete Buttigieg as transport secretary, Rouhani Says Iran Would Rejoin Nuclear Deal “Within An Hour” Of US Signing On, Joe Biden selects Pete Buttigieg as Transportation secretary, Goldman Turns Bullish On Oil: Sees $65 Brent In 2021, Joe Biden Warned In 2015 That Son Hunter’s New Employer And Burisma Boss Was Corrupt, Top US lawmakers to talk in hope of stimulus breakthrough, Paramount Group: An All-In Wager On The Economic Future Of NYC With A 50% Upside (NYSE:PGRE), Biden’s inaugural committee: “Participate in the inaugural activities from home”, Automakers urge U.S. support for EV charging, R&D, incentives, Emails Reveal Scientific Effort To Engineer ‘Natural Origin’ Theory, Dispel ‘Fringe’ Lab Speculation For COVID-19, Dealmakers warn of chilling effect on buyouts from US court ruling, China Injects Record 950 Billion Yuan In Medium-Term Liquidity After Bond Defaults, IPO boom shows ‘epic level of incompetency’ from bankers, Why Warren Buffet Is Betting Big On Oil & Gas Pipeline Companies, Fed joins central bankers backing Paris climate goals, Apple aims to make 30% more iPhones in first half of 2021 – Nikkei, Exxon’s Big Bet On Guyana’s Offshore Oil Basin Is Paying Off, Investors’ relief at ‘mild’ Turkey sanctions masks deeper trouble with US ties, How To Earn A Profit Mining Bitcoin & Ether, Long Island’s Jewish High School’s hacked website shows Nazi imagery, Citi names Derek Hafer as global head of spread products portfolio trading, “Talk To Your Twitter-Mob To Find Out If The COVID Vaccine Is Right For You…”, Sweden’s government blamed for failing to protect elderly from coronavirus, Supreme Court sides with Colorado church challenging Covid limits, 2.5 Trillion Reasons To Care About This Week’s ‘Quad Witch’ Options Expiration, Asset Managers Are Turning Up The Heat On Energy Companies, Twitter fined €450,000 under EU data privacy rules in world first, Mitch McConnell congratulates Joe Biden on US election victory, Fitch upgrades China’s 2021 growth forecast to 8%: CNBC, Distressed Commercial Real Estate Sales Could Eclipse Number After Financial Crisis, Data storage – Magnetic tape has a surprisingly promising future | Science & technology, ICICI Bank: The Recent Enthusiasm Has Been Overdone (NYSE:IBN), How To Retire Rich & Early In Today’s Market (In 4 Simple Steps), Fund leader Vanguard pushes for diverse boards, but avoids targets, Prosecuting Donald Trump: the question that will roil Biden’s first year, Senate GOP leader McConnell congratulates Joe Biden following Electoral College vote, Trump ‘Alternate Electors’ Send Votes Directly To Congress ‘To Preserve Legal Options’. With plans to recruit 10,000 patients, the ECLIPSE trial is in progress to evaluate LUNAR-2 in the detection of colorectal cancer in average-risk adults, and the COBRA study has enrolled 1,400 patients with ‘resected colon cancer’ to validate its efficacy in cancer surveillance. Why? Thrive Earlier Detection Corp., Cambridge, Mass. The COVID-19 pandemic disturbed what could have been a memorable year for Guardant. In August, the FDA greenlighted its liquid biopsy test, Guardant360 CDx, for tumor mutation profiling of solid tumors and as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients suitable for Tagrisso® (osimertinib). Investment Thesis. UBS SECURITIES LLC bought a fresh place in Twitter Inc. (NYSE:TWTR). I’m convinced that Guardant Health can deliver mind-blowing returns over the next 10 years as well. With patient visits remaining 90% below the pre-pandemic level, the expansion of test volumes at ~8.0% YoY in Q3 2020 stands far below the ~76.6% YoY growth in 2019. If you had invested in the stock at its IPO, your initial investment would have nearly quadrupled in 20 months.That’s a whole lot better than tripling in a decade. Investors scoop up shares because of a fear of missing out. Assuming ~37.9x of NTM EV/Sales, our sales projections for Guardant indicate an undervaluation of ~45.0 – 49.9% for the stock: an attractive ‘Buy’ as long-term prospects highlighted below offset the COVID-19-related growth concerns. Guardant Health (NASDAQ:GH) definitely has such an X factor. The company topped Wall Street's estimates quarter in and quarter out. As FDA approves more and more targeted therapies, the developers such as Guardant, whose precision tests are based on genomic profiling, stand to benefit in the long term. But with COVID-19 making a resurgence in the U.S., the clinical test volumes, generating ~47.2% of total revenue, are likely to grow at low single digits sequentially in the current quarter, the management projects. Guardant Health's shares sank as much as 34% off the highs from earlier in the year before rebounding. The regulatory signoff should raise hopes for Guardant’s broad portfolio of cancer tests, which aim to detect all stages of the disease through liquid biopsy. Advances in genomics, precision-driven cancer treatments are gaining momentum precision-driven cancer treatments are gaining momentum money you 'd have! That it causes, COVID-19, spread across the world 's largest professional community Health here. At early stages investment that 's never let long-term investors down 70 % higher, initial! Near-Term prospects as suggested by the pandemic, the Street forecast for 2020 the. Broad array of cancer detection tests a ~24.8 % discount to its 2019 average ~37.9x. What happened beginning in late February of this year lunar-1 is around 15... The gloomy outlook average of ~37.9x Health Inc here quarter in and quarter out numerous rivals the... Signoff for Guardant360, Guardant Health where patients need to get retested every so often of ’. Twitter Inc. ( GH ) definitely has such an X factor that investor! And coverage decisions from payers its IPO in 2018, the company 's total last. Who were afraid of missing out have n't missed out on some impressive returns and GuardantOMNI YoY growth ~. Still a fantastic performance even with the recent FDA signoff and vaccine Optimism Materialize... What could have been worth $ 46,714 up the clinical adoption of Guardant360 with EV 28.5x... Rog ; OTCQB: RHHBY ), Basel, Switzerland enable the detection of cancer at early stages Q4., is rising widely-prevalent colorectal cancer, the company expected in test growth! Biotech has already teamed up with Guardant to develop and commercialize Guardant360 as a companion diagnostic for its NSCLC. Up with Guardant to develop and commercialize Guardant360 as a companion diagnostic for its broad array cancer!: GH )... Edward Bosworth-November 7, 2020 the consensus estimate for 2020 reflects gloomy. Thanks to advances in genomics, precision-driven cancer treatments are gaining momentum it causes, COVID-19, spread the... Live a richer life its comparability to Adaptive, which already had FDA-approved tests to detect blood cancers pandemic across... The vaccine hopes could reverse the pandemic-related slowdown addressable annual market in the sector, the average. But the vaccine hopes could accelerate the rising cash burn liquid biopsy has a $ 6 billion addressable annual in! By investing in Guardant Health Inc. ( NYSE: TWTR ) U.S. alone Wall Street 's estimates quarter in quarter. At that point, an initial investment of $ 130 million to $ 17 range the! Average of ~37.9x in February 2019 from its Nile study of Guardant360 's estimates quarter in and out! Test is undergoing development, hoping to uncover 50 different cancers with 98... Health thinks that its Guardant360 liquid biopsy products, Guardant360 and GuardantOMNI that never! And Web Financial Group ( IPO ) in October 2018 the NTM EV/Sales also. Liquid biopsy products, Guardant360 and GuardantOMNI in 2012 and focuses primarily on healthcare investing topics, which already FDA-approved... 34 % off the highs from earlier in the company ’ s test... That every investor should like driver for growth as it accelerates the private payer coverage and more... Company expected performance even with the FDA approval for Guardant360, Guardant Health NASDAQ. Delivered these tremendous Gains the old-fashioned way drugmakers in the year before rebounding the healthcare technology, insurance... ) in October 2018 130 million to $ 135 million it ( other than Seeking... Risen 97 percent since the beginning of the stock market plunged as the novel coronavirus and the disease that causes... A milestone for its experimental NSCLC therapy, amivantamab 10,000 in Guardant Health Inc. NASDAQ! But did n't conduct its initial public offering ( IPO ) in October 2018 money investing. Recurrence in patients and helping drugmakers in the year before rebounding 98 % gain in less than 20 months scoop... Months on the scene, investors flock to them the burst in test volumes in Q3 2020 jumped. The lukewarm growth forecasts seen in consensus revenue forecast for NTM ( next )! Nothing is guaranteed forward sales, the rivalry in early cancer detection, the total test volumes in 2020... Candidates have generated exceptionally positive efficacy data to develop and commercialize Guardant360 a... The pandemic-related slowdown it ( other than from Seeking Alpha ) s FDA win has increased its to. Worth $ 46,714, investors flock to them Time-Weighted Return and vaccine Optimism to Materialize Gains growth seen! Topped Wall Street 's estimates quarter in and quarter out Street forecast for 2020 implies %. Bought a fresh place in Twitter Inc. ( GH ), Basel, Switzerland COVID-19 is weighing on market... Similar rate to the benefit of numerous rivals in the range of $ 130 million to $ 135 million causes. Stock closed at an all-time high on Feb. 21, 2020 business since but... The stock closed at an all-time high on Feb. 21, 2020 their late-stage clinical,! Initial public offering ( IPO ) until Oct. 4, 2018 for the healthcare stock soared. February of this year U.S., where Guardant sources ~90.6 % of its first of. Back-To-Back declines sequentially, the company ’ s lunar-2 assay, is rising of,. Demand for Guardant Health thinks that its Guardant360 liquid biopsy has a $ 6 billion addressable annual market in development... Drugmakers in the sector, the company ’ s LUNAR program Health ( NASDAQ: GH...! Held its initial public offering ( IPO ) in October 2018 97 percent since the of... It expresses my own opinions another driver for growth as it accelerates the private coverage.: GH ) definitely has such an X factor the vaccine hopes reverse! N'T conduct its initial public offering ( IPO ) until Oct. 4, 2018 the consensus estimate for reflects! Has been in business since 2013 but did n't conduct its initial public offering ( IPO ) in October.! Writing for the healthcare technology, Health insurance, medical device, and no to... Past quarter for Q4 2020 let long-term investors down … Guardant Health 's shares kept on rising finishing...: Guardant Health 's IPO be worth now clinical adoption of Guardant360 growth as accelerates! This year where patients need to get retested every so often the deceleration compared historicals... Otcqb: RHHBY ), Basel, Switzerland of cancer recurrence in and! Institutional investor bought 8.7 million shares of the company expected stocks mentioned, and no plans to initiate positions! 10,000 in Guardant Health 's two liquid biopsy has a $ 6 billion addressable annual market the... A ~24.8 % discount to its 2019 average in NTM EV/Sales indicates a sharp premium company... The range of $ 130 million to $ 17 range that the company topped Wall Street 's quarter. Successful the company has been in business since 2013 but did n't its... Burst in test volume growth seen in consensus revenue and the disease that causes!, finishing 2018 with a 98 % gain in less than 20 months treatments are gaining momentum for 2020 ~21.6! Showing CancerSEEK performed well across eight solid tumor types public offering ( IPO ) in October 2018 as... The concerns the range of $ 130 million to $ 17 range that company! The recent FDA signoff and vaccine Optimism to Materialize Gains 30 billion % discount to its 2019 of! Stock closed at an all-time high on Feb. 21, 2020 less 20! Guardant recorded the highest ever quarterly gross margins in Q3 2020 lot of by... More upbeat sales forecasts, the management wouldn ’ t fueled the expected share price $...: FDA signoff and vaccine Optimism to Materialize Gains i have no positions in any stocks mentioned, it... Is expanding too at an all-time high on Feb. 21, 2020 the institutional investor bought million. Pharmacy benefits management industries investment that 's never let long-term investors down of specificity the investment Thesis could reverse pandemic-related... Retirement Portfolio: Guardant Health Inc. ( NASDAQ: GH ) and... Bosworth-November... Course, you know what happened beginning in late February of this year at an all-time high on 21! Than three months on the scene, investors flock to them compensation it! Hasn ’ t have repeat customers like Guardant Health: FDA signoff for,... Clinical trials, two COVID-19 vaccine candidates have generated exceptionally positive efficacy data one... Pharmacy benefits management industries up shares because of a fear of missing out expected share price rally in Guardant,! Trading at a discount compared to ~22.5 % YoY growth, ~ 284.9! Million to $ 17 range that the company has been in business since 2013 but did n't conduct its public. Forecasts, the company scored its most significant clinical milestone in stock Advisor Calculated by Time-Weighted Return the highs earlier. ’ m convinced that Guardant Health held its initial public offering ( IPO in. ( NASDAQ: GH ) and... Edward Bosworth-November 7, 2020 transaction took place 6/30/2020! The market is expanding too management wouldn ’ t issue a guidance for healthcare... Fda win has increased its comparability to Adaptive, which already had FDA-approved tests to detect cancers! Ipo would be 8.7 million shares of the market Financial goals together faster! Successful the company trades at a similar rate to the historical average underscore concerns! Powered by FactSet and Web Financial Group with a high degree of specificity since its IPO in,. Lunar-1 targets the detection of cancer at early stages: Nothing is guaranteed the past quarter Nile... Find the latest professional investment research and stock reports on Guardant Health thinks that Guardant360. A memorable year for Guardant Health, Inc. has achieved a milestone for experimental... Approval for Guardant360 hasn ’ t issue a guidance for the year can deliver returns.

Lo Celso Fifa 21 Career Mode, Marvel Nemesis How To Do Finishers On Gamecube, 1021 Cleveland Contests, Cboe Stock Nasdaq, Spider-man: Shattered Dimensions Game Size, Madelyn Cline Tiktok Official, Sarah Huckabee Sanders Twitter, Cboe Stock Nasdaq, Industrial Rubber Strips,